NMDA receptor challenge with dextromethorphan - Subjective response, neuroendocrinological findings and possible clinical implications

Journal of Neural Transmission

Volumn 107, Issue 6, 2000, Pages 701-714

  Soyka, M ^a   Bondy, B ^b   Eisenburg, B ^b   Schutz C G ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b NONE

Author keywords

Alcohol; Alcoholism; Dextrometorphan; Glutamate; Pharmacotherapy

Indexed keywords

ALCOHOL; DEXTROMETHORPHAN; GLUTAMATE RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ADULT; ALCOHOLISM; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DETOXIFICATION; DRUG EFFECT; HUMAN; MALE; NEUROENDOCRINE SYSTEM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0034040943     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007020070071     Document Type: Article

References (56)

1. al Quatari M, Bouchenafa O, Littleton J (1998) Mechanisms of action of acamprosate, part II. Ethanol dependence modifies effects of acamprosate on NMDA receptor binding in membranes from rat cerebral cortex. Alcohol Clin Exp Res 22: 810-814
2. Berton F, Francesconi WG, Madamba SG, Zieglgänsberger W, Siggins GR (1998) Acamprosate enhances N-methyl-D-apartate receptor-mediated neurotransmission but inhibits presynaptic GABA (B) receptors in nucleus accumbens neurons. Alcohol Clin Exp Res 22: 183-191
3. Bisaga A, Gianelli P, Popik P (1997) Opiate withdrawal with dextromethorphan. Am J Psychiatry 154: 584
4. Bolo N, Nedelec JF, Muzet M, de Witte P, Dahchour A, Durbin P, Macher JP (1998) Central effects of acamprosate, part 2. Acamprosate modifies brain in-vivo proton magnetic resonance spectrum in healthy young male volunteers. Psychiatry Res Neuroimaging 82: 115-127
5. Boyd AE, Lebowitz HE, Pfeiffer JB (1970) Stimulation of human growth hormone secretion by L-DOPA. N Engl J Med 283: 1425-9
6. Breier A (1999) Cognitive deficits in schizophrenia and its neurochemical basis. Br J Psychiatry 174 [Suppl 37]: 16-18
7. Breier A, Malhotra AK, Pinals DA, Weisenfeld NI, Pickar D (1997) Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Am J Psychiatry 154: 805-811
8. Curran SL, Andrykowsky MA, Studts JL (1995) Short form of the Profile of Mood States (POMS-SF) Psychometric Information. Psychological Assessment 7/1: 80-83
9. Dahchour A, De Witte P, Bolo N, Nedelec JF, Muzet M, Durbin P, Macher JP (1998) Central effects of acamprosate, part 1. Acamprosate blocks the glutatamate increase in the nucleus accumbens microdialysate in ethanol withdrawn rats. Psychiatry Res Neuroimaging 82: 107-114
10. Danysz W, Jankowska E, Glazewski S, Kostowski W (1992) The involvement of NMDA receptors in acute and chronic effects of ethanol. Alcohol Clin Exp Res 16: 499-504
11. Danysz W, Parsons CG, Bresink I, Quack G (1995) Glutamate in CNS disorders. A revived target for drug development? DN&P 8: 261-277
12. Dettling M, Heinz A, Dufeu P, Rommelspacher H, Graf KJ, Schmidt LG (1995) Dopaminergic responsitivity in alcoholism: trait, state, or residual marker? Am J Psychiatry 152 (9): 1317-1321
13. Dilling H, Mombour W, Schmidt MH (1993) Internationale Klassifikation psychischer Störungen ICD-10. Hans Huber, Bern Göttingen Toronto Seattle
14. Elliott K, Kest B, Man A, Kao B, Inturrisi CE (1995) N-Methyl-D-Aspartate (NMDA) receptors, Mu and Kappa opioid tolerance, and perspectives on new analgesic drug development. Neuropsychopharmacology 13: 347-356
15. Gavend M, Mallare M, Dematteis M, Baragatti G (1995) Discriminative stimulus properties of dextromethorphan in rats. Biomed Pharmacother 49: 456-464
16. Heyser CJ, Schulteis G, Durbin P, Koob GF (1998) Chronic acamprosate eliminates the alcohol deprivation effect while having limited effects on baseline responding for ethanol in rats. Neuropsychopharmacology 18: 125-133
17. Hölter SM, Danysz W, Spanagel R (1996) Evidence of alcohol-craving properties of memantine. Eur J Pharmacol 314: R1-R2
18. Iaboni RP, Aronowitz JS (1995) Dextromethorphan abuse in a dually diagnosed patient. J Nerv Ment Dis 183 (5): 341-342
19. Kalivas PW (1995) Interactions between dopamine and excitatory amino acids in behavioral sensitization to psychostimulants. Drug Alcohol Depend 37: 95-100
20. Kornhuber J, Weller M (1997) Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy. Biol Psychiatry 41: 135-144
21. Kratzer U, Schmidt WJ (1998) The anti-craving drug acamprosate inhibits the conditioned place aversion induced by naloxone-precipitated morphine withdrawal in rats. Neurosci Lett 252: 52-56
22. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB, Charney DS (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51: 199-214
23. Krystal JH, Petrakis IL, Webb E, Cooney NL, Karper LP, Namanworth S, Stetson P, Trevisan LA, Charney DS (1998) Dose-related-like effects of the NMDA antagonist, ketamine, in recently detoxified alcoholics. Ach Gen Psychiatry 55: 354-360
24. Lahti AC, Koffel B, LaPorte D, Tamminga CA (1995) Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13: 9-19
25. Littleton J (1995) Acamprosate - how does it work? Addiction 90: 1179-1188
26. Lovinger DM (1993) Excitotoxicity and alcohol-related brain damage. Alcohol Clin Exp Res 17: 19-27
27. Lovinger DM, White G, Weight FF (1989) Etanol inhibits NMDA-activated ion current in hippocampal neurons. Science 243: 1721
28. Lovinger DM, White G, Weight FF (1990) NMDA receptor-medicated synaptic excitation selectively inhibited by ethanol in hippocampal slice from adult rat. J Neurosci 10: 280-284
29. Maisto SA, Conners GJ, Tucker JA, McCollam JB, Addesso VJ (1980) Validation of the Sensation Scale, a measure of subjective physiological responses to alcohol. Behav Res Ther 18: 37-43
30. Müller-Spahn F, Modell S, Ackenheil M, Brachner A, Kurtz G (1998) Elevated response of growth hormone to graded doses of apomorphine in schizophrenic patients. J Psychiatr Res 32: 265-271
31. Murray S, Brewerton T (1993) Abuse of over-the counter dextromethorphan by teenagers. S Med J 86 (10): 1151-1153
32. Naassila M, Hammoumi S, Legrand E, Durbin P, Daoust M (1998) Mechanisms of action of acamprosate, part I. Characterization of spermidine-sensitive acamprosate binding site in rat brain. Alcohol Clin Exp Res 22: 802-809
33. Newcomer JW, Farber NB, Jevtovic-Todorovic V, Selke G, Melson AK, Hershey T, Craft S, Olney Jw (1998) Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology 20: 106-118
34. Paille FM, Guelfi JD, Perkins AC, et al. (1995) Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol 30: 239-247
35. Plasecki J, Koros E, Dyr W, Kostowski W, Danysz W, Bienkowski P (1998) Ethanol-reinforced behavior in the rat: effects of uncompetive NMDA receptor antagonist, memantine. Eur J Pharmacol 354: 135-143
36. Putzke J, Spanagel R, Tolle TR, Zieglgänsberger W (1996) The anti-craving drug acamprosate reduces c-fos expression in rats undergoing ethanol withdrawal. Eur J Pharmacol 317: 39-48
37. Sass H, Soyka M, Mann K, Zieglgänsberger W (1996) Relapse prevention by acamprosate: results from a placebo controlled study in alcohol dependence. Arch Gen Psychiatry 53: 673-680
38. Schmidt LG, Dettling M, Graef KJ, Heinz A, Kuhn S, Podschus J, Rommelspacher H (1996) Reduced dopaminergic function in alcoholics is related to severe dependence. Biol Psychiatry 39 (3): 193-198
39. Schuetz CG, Soyka M (2000) Dextrometorphan challenge in alcoholics and healthy controls. Arch Gen Psychiatry (in press)
40. Soyka M (1996) Clinical efficacy of acamprosate in the treatment of alcoholism. In: Soyka M (ed) Acamprosate in relapse prevention of alcoholism. Springer, Berlin Heidelberg New York, pp 155-171
41. Soyka M (1997) Relapse prevention in alcoholism: recent advances and future possibilities. CNS Drugs 7: 313-327
42. Spanagel R, Hölter SM, Allingham K, et al. (1996a) Acamprosate and alcohol. I. Effects on alcohol intake following alcohol deprivation in the rat. Eur J Pharmacol 305: 39-44
43. Spanagel R, Putzke J, Stefferl A, et al. (1996b) Acamprosate and alcohol: effects on alcohol withdrawal in the rat. Eur J Pharmacol 305: 45-50
44. Spanagel R, Zieglgänsberger W, Hundt W (1996c) Acamprosate and alcohol. III. Effects on alcohol discrimination in the rat. Eur J Pharmacol 305: 51-56
45. Spanagel R, Sillaber I, Zieglgansberger W, Corrigall WA, Stewart J, Shaham Y (1998) Acamprosate suppresses the expression of morphine induced sensitization in rats but does not affect heroin self administration or relapse induced by heroin or stres. Psychopharmacology 139: 391-401
46. Tortella FC (1989) Dextromethorphan and neuromodulation: old drug coughs up new activities. Trends Pharmacol Sci 10: 501-507
47. Trevisan L, Fitzgerald LW, Brose N, Gasic GP, Heinemann SF, Duman RS, Nestler EJ (1994) Chronic ingestion of ethanol up-regulates NMDA R1 subunit immunoreactivity in rat hippocampus. J Neurochem 62: 1635-1638
48. Tsai G, Gastfriend DR, Coyle J (1995) The glutamateric basis of human alcoholism. Am J Psychiatry 152: 332-340
49. Tsai G, Passani LA, Slusher BS, Carter R, Baer L, Kleinman JE, Coyle JT (1995) Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch Gen Psychiatry 52; 829-836
50. Vollenweider FX, Leenders KL, Scharfetter C, Antonini A, Maguire P, Missimer J, Angst J (1997) Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and (18F) fluorodeoxyglucose (FDG). Eur Neuropsychopharmacol 7: 9-24
51. Whitton PS (1997) Glutamatergic control over brain dopamine release in vivo and in vitro. Neurosci Biobehav Rev 21 4: 481-488
52. Whitworth AB, Fischer F, Lesch OM, et al. (1996) Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet 347: 1438-1442
53. Wiley JL (1997) Behavioral pharmacology of N-Methyl-D-aspartate antagonists: implications for the study and pharmacotherapy of anxiety and schizophrenia. Exp Clin Psychopharmacol 5: 365-374
54. Zieglgänsberger W, Zeise M (1992) Calcium-diacetyl-homotaurinate which prevents relapse in weaned alcoholics decreases the action of excitatory amino acids in neo-cortical neurons of the rat in vitro. In: Sellers EM, Naranjo CA (eds) Novel pharmacological interventions for alcoholism. Springer, Berlin Heidelberg New York Tokyo, pp 337-341
55. Zieglgänsberger W, Hauser C, Wetzel C, et al. (1996) Actions of acamprosate on neurons of the central nervous system. In: Soyka M (ed) Acamprosate in relapse prevention of alcoholism. Springer, Berlin Heidelberg New York Tokyo, pp 65-70
56. Zilles K, Rehkämper G (1998) Funktionelle Neuroanatomie. Springer, Berlin Heidelberg New York Tokyo